Trial site
Hospital Privado Centro Medico de Cordoba
Córdoba, X5016KEH, ArgentinaNot linked to an institution yet
- 12running trials
- 6closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Completed6 trials
- Recruiting4 trials
- Lead sponsor
- Janssen Research & Development, LLC8 trials
- Pfizer4 trials
- Hoffmann-La Roche2 trials
- Boehringer Ingelheim1 trial
- Shire1 trial
- and 2 more
Running trials
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326· Phase 3· Takeda· Source
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error